Aristotle University Of Thessaloniki (AUTH)
Μελέτη μεθυλίωσης του DNA σε παιδιά και εφήβους με αυτοάνοσα νοσήματα του θυρεοειδούς αδένα
Abstract
dc:descriptionIntroduction: Hashimoto Thyroiditis (HT) and Graves' Disease (GD) are conditions known to be caused by abnormal immune response against self-antigens. Biological processes at molecular lever are still poorly understood. A few epigenetic studies have been published so far. Objective: To investigate whether there are differences in DNA methylation within the promoters of HLADRB1, CD40L, FOXP3, CTLA4, FCRL3, IL2RA and PTPN22 genes between young patients with autoimmune thyroid disease and healthy individuals of similar age, sex and body mass index. Additionally, to explore whether there are factors from personal, family, obstetric, perinatal history as well as clinical and laboratory measurements, or other demographic and socioeconomic factors, that are significant determinants of DNA methylation at the genetic sites tested. Patients and Methods: 60 patients with HT (11.7±0.3 years), 10 with GD (12.1±0.4 years), 25 with concurrent diagnosis of Τype 1 Diabetes and Hashimoto Thyroiditis (T1DM+HT) (12.3±0.4 years), and 55 healthy controls (11.1±0.3 years) without any personal or family history of autoimmune disease, at least at first-grade relatives, were recruited. DNA was extracted from whole blood and then modified with sodium bisulfite. The percentage of DNA methylation within the above mentioned gene promoters was quantified, using specific primers for modified DNA, by analyzing melting curves obtained during real-time PCR. Results: Differences in DNA methylation percentages among study groups were detected within the promoters of IL2RA (HT: 36.3±1.4%, T1DM+HT: 35.3±2.2%, GD: 26.0±3.8%, controls: 41.3±1.5%, p<0.001), ΡΤΡΝ22 (HT: 39.9±3.1%, T1DM+HT: 20.3±2.4%, GD: 32.6±7.8%, controls: 27.1±2.4%, p<0.001), CTLA4 (HT: 42.4±3.0%, T1DM+HT: 71.4±4.7%, GD: 45.2±6.7%, controls: 42.3±3.7%, p<0.001) and FOXP3 (HT: 90.1±1.4%, T1DM+HT: 97.3±1.0%, GD: 86.2±5.4%, controls: 93.2±1.1%, p=0.004) but not HLADRB1 (HT: 82.7±2.2%, T1DM+HT: 74.9±3.9%, GD: 88.1±4.5%, controls: 85.2±2.3%), CD40L (HT: 67.5±3.4%, T1DM+HT: 65.9±6.0%, GD: 62.6±6.0%, controls: 60.5±3.8%) or FCRL3 (HT: 77.1±2.1%, T1DM+HT: 76.6±2.8%, GD: 85.0±3.1%, controls: 76.8±1.8%) (p>0.05 in all cases). Moreover, factors that were found to be independently associated with DNA methylation within the promoters of the tested genes were sex (CD40L), the presence of another autoimmune disease (CTLA4, FOXP3, PTPN22), diagnosis of autoimmune thyroid disease (IL2RA), impaired thyroid function (FCRL3), the presence of goiter (PTPN22), as well as other factors such as father's educational level (CTLA), maternal smoking during pregnancy (FCRL3), gestational diabetes (FOXP3) and body mass index z-score (CD40L, FCRL3) (adjusted p≤0.05 in all cases). Conclusions: This study suggests that altered DNA methylation in different gene promoters does exist in patients with autoimmune thyroid disease. Factors that are significant determinants of DNA methylation are also described. These differences remain to be shown whether they are related with variability in the expression of the corresponding genes, thus shedding light in the aetiopathogenesis of autoimmune thyroid disease in childhood and adolescence.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kyrgios, Ioannis
- Κύργιος, Ιωάννης
Subjects
dc:subject × 23- Aυτοάνοση θυρεοειδική νόσος
- Νόσος graves
- Θυρεοειδίτιδα Hashimoto
- Μεθυλίωση DΝΑ
- Επιγενετική
- Παιδιά και έφηβοι
- HLA-DRB1
- CD40L
- FOXP3
- CTLA4
- FCRL3
- IL2RA
- PTPN22
- Autoimmune thyroid disease
- Graves' disease
- Hashimoto thyroiditis
- DNA methylation
- Epigenetics
- Children and adolescents
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/47218